ArticlePostepy dermatologii i alergologii2025
Real-world evidence - biosimilars can successfully substitute biologics in psoriasis and hidradenitis suppurativa.
Article in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Medical approval of biosimilars requires comparable quality, biological activity, safety as well as efficacy of the reference biologic drug. Aim: The aim of this study is to examine whether biosimilars for adalimumab and etanercept can be prescribed as substitutes for the originator drugs in a real-world patient collective. Material and methods: For the analysis, 259 outpatients with psoriasis (94%) or hidradenitis suppurativa (6%) were retrospectively examined regarding disease burden, side effects and symptoms during and following the transition from a biologic to a biosimilar and, if applicable, after switching back to the originator drug. Results: Of the analysed cohort, 76.4% of patients had previously received the adalimumab originator, Humira Conclusions: This real-world data shows that biosimilar therapy is successful in around 80% of the population observed. In the event of exacerbation of symptoms or occurrence of side effects, switching back to the biologic might be necessary and was proved to be problem-free.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.